Abstract:Background. Liver cancer, particularly hepatocellular carcinoma (HCC), is the fourth leading cause of cancer-related death worldwide. Sorafenib is a crucial drug for the treatment of advanced HCC, but it is difficult to meet the challenge of increasing clinical demands due to its severe side effects and drug resistance. Hence, development of novel antitumor drugs is urged. Previous studies showed that pseudolaric acid B (PAB) could reduce the expression of protein kinase B (PKB/Akt), a downstream effector of Notch signaling, facilitating cell apoptosis in HCC. The disruption of Notch signaling was verified to exacerbate malignant progression and drug resistance, however, the antitumor effect of PAB on Notch signaling in HCC remains unclear. Thus, this study aims to investigate the anti-HCC effect of PAB in association with the regulation of Notch1/Akt signaling. Methods. CCK-8 assay and transwell assay were used to examine the cell proliferation and invasion in Huh7 cells after treatment with PAB and a Notch inhibitor DAPT. Moreover, the cell cycle of Huh7 cells after treatment with PAB was analyzed using flow cytometry. Finally, the changes of Notch1, Jagged1, Hes1, and Akt expression at the protein and mRNA level in Notch1/Akt signaling in Huh7 cells after treatment with PAB and DAPT were analyzed using immunofluorescence assay and real-time qPCR. Results. The proliferation rate of Huh7 cells exposed to PAB of 0.5, 1, 2, 4, 8, 10, 20, 40, 80, 100, and 200 μmol/L revealed a time-and dose-dependent decrease in vitro, showing cell cycle arrest at G2/M phase P<0.05. Furthermore, compared with the untreated group, at the concentration of 40 μmol/L, the proliferation rate and invasion rate of Huh7 cells in PAB, DAPT, and PAB-DAPT combination (PAB + DAPT) group were significantly decreased P<0.05, but the PAB + DAPT showed no synergistic antiproliferation and anti-invasion effect in comparison with PAB treatment alone P>0.05. In addition, compared with the untreated group, PAB and DAPT alone significantly downregulated the expression of Notch1, Jagged1, Hes1, Akt mRNA, or/and protein in Huh7 cells P<0.05, but there was no significant difference in synergistic downregulated effect between the PAB + DAPT group and the PAB group P>0.05. Conclusion. PAB can suppress proliferation and invasion of HCC cells through downregulating the expression of Notch1/Akt signaling protein and mRNA, and may be a potential novel antitumor drug candidate for the clinical treatment of HCC in the future.

Pseudolaric Acid B Inhibits FLT4-induced Proliferation and Migration in Non-small Cell Lung Cancer

Pseudolaric Acid B Induces Mitotic Arrest and Apoptosis in Both Imatinib-Sensitive and -Resistant Chronic Myeloid Leukaemia Cells.

Pseudolaric Acid B Exhibits Anti-Cancer Activity on Human Hepatocellular Carcinoma Through Inhibition of Multiple Carcinogenic Signaling Pathways

Pseudolaric acid B exerts antitumor activity via suppression of the Akt signaling pathway in HeLa cervical cancer cells.

Antitumor Effect of Pseudolaric Acid B Involving Regulation of Notch1/Akt Signaling Response in Human Hepatoma Cell in Vitro

Angiogenesis Inhibition and Cell Cycle Arrest Induced by Treatment with Pseudolarix Acid B Alone or Combined with 5-Fluorouracil

Pseudolaric Acid B Inhibits Neuroglioma Cell Proliferation Through DNA Damage Response

Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin.

Pseudolaric acid B triggers cell apoptosis by activating AMPK/JNK/DRP1/mitochondrial fission pathway in hepatocellular carcinoma.

Pseudolaric Acid B Triggers Cell Apoptosis by Activating AMPK/JNK/DRP1/mitochondrial Fission Pathway in Hepatocellular Carcinoma

In vitro antimetastatic potential of pseudolaric acid B in HSC-3 human tongue squamous carcinoma cell line

Pseudolaric Acid B Induces Endometrial Cancer Ishikawa Cell Apoptosis and Inhibits Metastasis Through AKT-GSK-3β and ERK1/2 Signaling Pathways

Pseudolaric Acid B Inhibits Angiogenesis and Reduces Hypoxia-Inducible Factor 1α by Promoting Proteasome-Mediated Degradation

Design, synthesis, and in vivo and in vitro biological screening of pseudolaric acid B derivatives as potential anti-tumor agents

Pseudolaric Acid B Inhibits Angiogenesis And Reduces Hypoxia-Inducible Factor 1 Alpha By Promoting Proteasome-Mediated Degradation

Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells

Pseudolaric Acid B Targets CD147 to Selectively Kill Acute Myeloid Leukemia Cells

Pseudolaric acid B inhibits proliferation in SW579 human thyroid squamous cell carcinoma.

Pseudolaric Acid B Induces Growth Inhibition and Caspase-Dependent Apoptosis on Head and Neck Cancer Cell lines through Death Receptor 5

Liriopesides B Induces Apoptosis and Cell Cycle Arrest in Human Non‑small Cell Lung Cancer Cells.

Explore the Mechanism of Inhibitory Effects of Pseudolaric Acid B on MCF-7 Cells by High Content Analysis